Last reviewed · How we verify
Niclosamide Pill
Niclosamide Pill is a Small molecule drug developed by Chulalongkorn University. It is currently FDA-approved. Also known as: Telehealth monitoring.
At a glance
| Generic name | Niclosamide Pill |
|---|---|
| Also known as | Telehealth monitoring |
| Sponsor | Chulalongkorn University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community (PHASE4)
- Niclosamide for Mild to Moderate COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Niclosamide Pill CI brief — competitive landscape report
- Niclosamide Pill updates RSS · CI watch RSS
- Chulalongkorn University portfolio CI
Frequently asked questions about Niclosamide Pill
What is Niclosamide Pill?
Niclosamide Pill is a Small molecule drug developed by Chulalongkorn University.
Who makes Niclosamide Pill?
Niclosamide Pill is developed and marketed by Chulalongkorn University (see full Chulalongkorn University pipeline at /company/chulalongkorn-university).
Is Niclosamide Pill also known as anything else?
Niclosamide Pill is also known as Telehealth monitoring.
What development phase is Niclosamide Pill in?
Niclosamide Pill is FDA-approved (marketed).
Related
- Manufacturer: Chulalongkorn University — full pipeline
- Also known as: Telehealth monitoring
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing